Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial

J Am Acad Dermatol. 2021 Feb;84(2):495-497. doi: 10.1016/j.jaad.2020.05.003. Epub 2020 May 7.

Authors

Joseph F Merola¹, Robert Sidbury², Andreas Wollenberg³, Zhen Chen⁴, Annie Zhang⁵, Brad Shumel⁴, Ana B Rossi⁶

Affiliations

¹ Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Seattle Children's Hospital, Seattle, Washington.
³ Ludwig-Maximilian University, Munich, Germany.
⁴ Regeneron Pharmaceuticals, Inc., Tarrytown, New York.
⁵ Sanofi Genzyme, Cambridge, Massachusetts.
⁶ Sanofi Genzyme, Cambridge, Massachusetts. Electronic address: Ana.Rossi@sanofi.com.

PMID: 32387659
DOI: 10.1016/j.jaad.2020.05.003

No abstract available

Publication types

Clinical Trial, Phase III
Letter
Randomized Controlled Trial

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / administration & dosage*
Antibodies, Monoclonal, Humanized / adverse effects
Dermatitis, Atopic / diagnosis
Dermatitis, Atopic / drug therapy*
Double-Blind Method
Female
Humans
Injections, Subcutaneous
Male
Self Report
Severity of Illness Index
Symptom Flare Up
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
dupilumab